BioLineRx Announces Results from Phase 1/2 Study for Celiac Treatment By: Benzinga via Benzinga July 16, 2014 at 07:01 AM EDT BioLineRx Ltd. (NASDAQ: BLRX) (TASE: BLRX), a clinical-stage biopharmaceutical company dedicated to identifying, in-licensing and ... Read More >> Related Stocks: Biolinerx Ltd ADR